edaravone + furosemide

Edaravone + furosemide is a therapeutic combination consisting of the neuroprotective agent edaravone and the loop diuretic furosemide. Edaravone functions as a potent free radical scavenger, specifically targeting reactive oxygen species (ROS) and peroxynitrite to mitigate oxidative stress-induced neuronal death, a key pathology in acute ischemic stroke and amyotrophic lateral sclerosis (ALS). Furosemide acts by inhibiting the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, promoting diuresis and natriuresis. This combination is primarily investigated and utilized in the management of acute cerebral infarction, where edaravone provides neuroprotection while furosemide addresses associated cerebral edema. While both components are individually approved for various indications, they are typically administered as separate intravenous formulations in a clinical setting, particularly in East Asian medical practice.

Other names

edaravone and furosemide